EI
VYNT

EAM Investors’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

EAM Investors’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-712
Closed -$422K – 361
2017
Q2 		$422K Sell
712
-74
-9% -$43.3K 0.07% 281
2017
Q1 		$483K Buy
+786
New +$280K 0.08% 293
2015
Q4 		– Sell
-866
Closed -$1.02M – 366
2015
Q3 		$1.02M Buy
866
+6
+0.7% +$9.19K 0.16% 260
2015
Q2 		$1.52M Buy
+860
New +$1.34M 0.18% 225
2013
Q4 		– Sell
-301
Closed -$916K – 366
2013
Q3 		$916K Buy
+301
New +$515K 0.18% 294

Other funds holding VYNT

PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Granahan Investment Management
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
FCM
Fairbanks Capital Management Rancho Santa Fe, California $169M AUM 12.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DM
Diker Management New York $130M AUM 97.77% 1-Year Est. Return
Wedbush Securities
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
TDC
Thompson Davis & Co Richmond, Virginia $167M AUM 33.45% 1-Year Est. Return

EAM Investors's VYNT Position: Q3 2017 in Review

EAM Investors sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q3 2017, closing a stake of 712 shares — an estimated $422K sold.

EAM Investors first reported a position in VYNT in Q3 2013 and held it in 5 quarters. The position peaked at $1.52M in Q2 2015. 26 funds tracked by Wall St. Rank hold VYNT as of Q3 2017.

  • EAM Investors reported no remaining Vyant Bio, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • EAM Investors sold 712 Vyant Bio, Inc. Common Stock shares in Q3 2017, an estimated $422K.
  • EAM Investors first reported a position in Vyant Bio, Inc. Common Stock in Q3 2013 and held it in 5 quarters.
  • EAM Investors's Vyant Bio, Inc. Common Stock position peaked at $1.52M in Q2 2015.
  • 26 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q3 2017.

Based on EAM Investors's 13F filing for Q3 2017, filed 8 Nov 2017.